Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.
2.

Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder.

Wilens TE, Biederman J, Spencer TJ, Frazier J, Prince J, Bostic J, Rater M, Soriano J, Hatch M, Sienna M, Millstein RB, Abrantes A.

J Clin Psychopharmacol. 1999 Jun;19(3):257-64.

PMID:
10350032
3.

Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction.

Conners CK, Taylor E.

Arch Gen Psychiatry. 1980 Aug;37(8):922-30.

PMID:
7406656
4.

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.

Rösler M, Fischer R, Ammer R, Ose C, Retz W.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9. doi: 10.1007/s00406-008-0845-4. Epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):368.

PMID:
19165529
5.

Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report.

Wood DR, Reimherr FW, Wender PH, Johnson GE.

Arch Gen Psychiatry. 1976 Dec;33(12):1453-60.

PMID:
793563
6.

Pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Wender PH.

J Clin Psychiatry. 1998;59 Suppl 7:76-9. Review.

7.

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.

Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N; SPD503 Study Group.

Pediatrics. 2008 Jan;121(1):e73-84. doi: 10.1542/peds.2006-3695.

PMID:
18166547
8.
9.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.

Pediatrics. 2004 Jul;114(1):e1-8.

PMID:
15231966
10.

Pharmacological treatment of attention deficit disorder, residual type (ADD,RT, "minimal brain dysfunction," "hyperactivity") in adults.

Wender PH, Wood DR, Reimherr FW.

Psychopharmacol Bull. 1985;21(2):222-31. No abstract available.

PMID:
3923527
11.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
12.

Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder.

Spencer T, Biederman J, Wilens T, Faraone S, Prince J, Gerard K, Doyle R, Parekh A, Kagan J, Bearman SK.

Arch Gen Psychiatry. 2001 Aug;58(8):775-82.

PMID:
11483144
13.

Methylphenidate effects on symptoms of attention deficit disorder in adults.

Mattes JA, Boswell L, Oliver H.

Arch Gen Psychiatry. 1984 Nov;41(11):1059-63.

PMID:
6388523
15.

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.

Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L; Atomoxetine ADHD/ODD Study Group.

Pediatrics. 2008 Feb;121(2):e314-20. doi: 10.1542/peds.2006-1880. Erratum in: Pediatrics.2008 Jul;122(1): 227.

PMID:
18245404
16.
17.

A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study.

Biederman J, Mick E, Faraone S, Hammerness P, Surman C, Harpold T, Dougherty M, Aleardi M, Spencer T.

J Clin Psychopharmacol. 2006 Apr;26(2):163-6.

PMID:
16633145
18.

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.

Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group.

Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28.

PMID:
19716683
19.

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.

Biol Psychiatry. 2006 May 1;59(9):829-35. Epub 2005 Dec 20. Erratum in: Biol Psychiatry. 2007 Jun 15;61(12):1402.

PMID:
16373066

Supplemental Content

Support Center